Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Obesity01:24

Obesity

347
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
347
Oogenesis02:07

Oogenesis

63.2K
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
63.2K
Infertility in Females01:28

Infertility in Females

216
Female infertility is defined as the inability to conceive after a year of regular, unprotected intercourse and affects about 10–15% of couples worldwide. The primary cause of female infertility is ovulatory disorders, which hinder the release of eggs. These disorders can be classified as hypothalamic amenorrhea, polycystic ovarian syndrome (PCOS), premature ovarian failure, and hyperprolactinemic anovulation disorders.
Endometriosis, a condition characterized by abnormal growth of...
216
Birth Control Methods01:22

Birth Control Methods

135
Vasectomy is a surgical form of male sterilization that involves severing and sealing the vasa deferentia, preventing sperm from mixing with semen during ejaculation. Because a vasectomy does not impact the testes' ability to produce testosterone, hormone levels, libido, and sexual function generally remain unchanged. While vasectomy is highly effective in preventing pregnancy, with a success rate near 99.85%, rare cases of recanalization (spontaneous reconnection) can occur. Although...
135
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Disorders of the Female Reproductive System01:24

Disorders of the Female Reproductive System

243
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
243

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Role of Artificial Intelligence in Addressing Menopausal Mental Health Challenges.

JBRA assisted reproduction·2026
Same author

Hormonal and metabolic effects of the administration of oral low-dose 17-β-estradiol (0.2 mg) in patients with Functional Hypothalamic Amenorrhea (FHA): A Retrospective Pilot Study.

Fertility and sterility·2026
Same author

European society of gynecology (ESG) position paper on the proposed terminology change from PCOS to PMOS.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2026
Same author

Contemporary Approaches Towards the Optimization of Embryo Implantation.

Journal of clinical medicine·2026
Same author

Immediate volume reduction following transvaginal ultrasound-guided thermal ablation (interstitial myolysis) of a symptomatic uterine fibroid.

Facts, views & vision in ObGyn·2026
Same author

Higher BMI is associated with vaginal microbiome alterations in women with PCOS.

Reproduction & fertility·2026

Related Experiment Video

Updated: May 14, 2025

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model
09:44

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model

Published on: March 5, 2022

2.9K

PCOS and Obesity: Contraception Challenges.

Blazej Meczekalski1, Melissa Rasi2, Christian Battipaglia3

  • 1Department of Gynecological Endocrinology, Poznan University of Medical Sciences, Poznan, Greater Poland, Poland.

Open Access Journal of Contraception
|May 12, 2025
PubMed
Summary

Polycystic ovary syndrome (PCOS) management involves selecting appropriate contraception. For obese PCOS patients, lower-dose ethinyl estradiol or progestin-only options are safer, with LNG-IUDs offering endometrial protection.

Keywords:
IUDPCOSobesityoral contraceptionpolycystic ovary syndrome

More Related Videos

Author Spotlight: Investigating the Mechanisms and Inducing Models of Polycystic Ovary Syndrome
04:49

Author Spotlight: Investigating the Mechanisms and Inducing Models of Polycystic Ovary Syndrome

Published on: July 5, 2024

860
A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome
08:20

A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome

Published on: October 2, 2018

11.1K

Related Experiment Videos

Last Updated: May 14, 2025

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model
09:44

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model

Published on: March 5, 2022

2.9K
Author Spotlight: Investigating the Mechanisms and Inducing Models of Polycystic Ovary Syndrome
04:49

Author Spotlight: Investigating the Mechanisms and Inducing Models of Polycystic Ovary Syndrome

Published on: July 5, 2024

860
A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome
08:20

A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome

Published on: October 2, 2018

11.1K

Area of Science:

  • Endocrinology
  • Gynecology
  • Reproductive Health

Background:

  • Polycystic ovary syndrome (PCOS) affects 5-10% of reproductive-aged women.
  • PCOS is linked to increased metabolic disturbances and high rates of overweight/obesity (40-85%).
  • Oral contraception is a primary PCOS treatment, but patient-specific factors like obesity require careful consideration.

Purpose of the Study:

  • To review contraceptive options for women with PCOS, emphasizing considerations for those who are overweight or obese.
  • To evaluate the safety and efficacy of various hormonal and non-hormonal contraceptive methods in the context of PCOS comorbidities.

Main Methods:

  • Literature review of current contraceptive guidelines and studies relevant to PCOS.
  • Analysis of hormonal and non-hormonal contraceptive efficacy and safety profiles.
  • Consideration of metabolic and cardiovascular risks associated with PCOS and obesity.

Main Results:

  • Low-dose ethinyl estradiol (EE) formulations or those with natural estrogens may be preferable for obese PCOS patients.
  • Progestin-only pills (POPs) present a safe contraceptive choice for obese PCOS patients with cardiovascular risks.
  • Non-oral methods (patches, rings) lack anti-androgenic progestins, potentially limiting efficacy for severe symptoms.
  • Levonorgestrel-releasing intrauterine devices (LNG-IUDs) offer effective contraception and endometrial protection, especially in obese PCOS patients.

Conclusions:

  • Contraceptive choice in PCOS should be individualized, balancing efficacy, safety, and comorbidities like obesity.
  • LNG-IUDs are a valuable option for PCOS patients, particularly those with obesity, due to their contraceptive and endometrial protective benefits.
  • Further research may be needed to optimize non-oral contraceptive strategies for PCOS patients with androgen excess.